Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787878 | 1.00 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL14387616 | 0.87 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL14424938 | 0.84 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL2784505 | 0.84 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL2784501 | 0.84 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL6896972 | 0.84 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL11459644 | 0.83 | MEN1 (0.37) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL5730035 | 0.83 | MEN1 (0.37) | MEN1KMT2AKDM4CNPC1RAB9A | |
| Bromide SCHEMBL6896974 | 0.82 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL14402649 | 0.82 | MEN1 (0.33) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100291118-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA (FR) | 2010-11-18 | — | — | US | disclosed |
| US-7767842-B2 | Class of γδ T cells activators and use thereof | INNATE PHARMA SA (FR) | 2010-08-03 | — | — | US | disclosed |
| US-20070249565-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | INNATE PHARMA S.A. (FR) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291118-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | CD4, IFNG, NFATC1 | MEN1 4438/4885KMT2A 3406/4885KDM4C 4129/4885 |
| US-20070249565-A1 | Class of Gamma Delta T Cells Activators and Use Thereof | CD4, IFNG, NFATC1 | MEN1 4438/4885KMT2A 3406/4885KDM4C 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.